Is Compounded GLP-1 Still Available in 2026? What the FDA Rule Means for You
Compare reviewed GLP-1 weight loss providers, billing commitments, and the treatments their links actually offer.
We may earn a commission through provider links. Matching affiliate offers and editorial priorities affect inclusion and suggested order in commercial guides. Scores are not clinical endorsements. Disclosure · Methodology
Compare the options first
Full comparison & price terms ↓A short preview in editorial order—not a guarantee of the cheapest total bill. Read the commitment terms before choosing.
$49/mo
Lower listed rate · not necessarily monthly billing
Semaglutide $49/mo or tirzepatide $89/mo with 12-month prepayment; $99/$129 month to month.
The Ranking
WellMedr
Compounded GLP-1 care with semaglutide shown at $49/mo or tirzepatide at $89/mo with 12-month prepayment; $99/$129 month to month. Verified affiliate coverage is weight loss only.
Editor’s take: WellMedr is our featured value-led compounded GLP-1 option, not a recommendation for unrelated men's-health or hair-loss treatment. Its public Trustpilot profile displayed 4.6/5 from 1,963 reviews when checked September 27, 2026; customer opinions do not establish clinical effectiveness. Recorded price terms were semaglutide $49/mo or tirzepatide $89/mo with 12-month prepayment; $99/$129 month to month. Compounded medications are not FDA-approved finished drugs. Confirm the exact prescription, pharmacy, dose progression, cancellation terms, and total commitment with the clinician before paying.
Full review →
SkinnyRx
Clinician-guided GLP-1 platform with both compounded and brand-name access plus overnight shipping.
Editor’s take: Premium positioning, premium catalog. If you want maximum optionality across GLP-1 modalities, this is the deepest menu on the site. The premium catalog comes at a premium price. If you want maximum optionality across GLP-1 modalities, SkinnyRx is the deepest menu on the site; if you want the lowest cost, look at Trimi or HealthRx.
Full review →
Direct Meds
Compounded GLP-1 clinic with transparent pricing and dedicated nurse support.
Editor’s take: Direct Meds is easier to compare than a program that separates its membership fee from medication, provided the public $249 and $297 starting points match the treatment path you are offered. Skip it if you specifically want brand-name GLP-1 access or in-state pickup.
Full review →
Shed Rx
GLP-1 clinic offering injections, oral semaglutide, drops, and lozenges plus brand-name Wegovy and Zepbound.
Editor’s take: A reasonable mid-priced pick when delivery flexibility matters. Verify auto-billing terms before signing up given mixed reports. Verify auto-billing terms before signing up given mixed reviews on cancellation. If delivery flexibility is your priority, compare ShedRx against Breeze Meds which also offers sublingual tirzepatide.
Full review →
Women-focused telehealth combining compounded GLP-1 weight loss with HRT support.
Editor’s take: A focused women's health pick. If you only want GLP-1, you'll find cheaper; if you want both GLP-1 and HRT in one clinic, this is one of the cleanest options on the list. If you only want GLP-1 without hormonal support, a lower-cost specialist like Trimi or HealthRx will be more cost-effective. If you want both GLP-1 and HRT in one clinic, Gala Health is one of the cleanest options available.
Full review →
FuturHealth
GLP-1 weight-loss platform combined with personalised nutrition and fitness coaching.
Editor’s take: Coaching is the differentiator. If you're going to use it, FuturHealth pulls ahead of cheaper, drug-only competitors. If you won't, save the money.
Full review →2026 Price Comparison. Published Price Terms
Compare the lower and higher listed rates, then read the billing conditions. A listed monthly equivalent may require prepayment; visits, medication, membership, or shipping can cost extra.
Recorded price-check dates: 30 August 2026. Per-provider dates below; these are not a guarantee of today's checkout price.
Rates use different billing terms and are not necessarily all-in or month-to-month. Confirm total charges and cancellation terms. Compounded medications are not FDA-approved finished drugs; pharmacy type alone does not establish legality or clinical suitability.
2 providers · Trustpilot scores are customer opinions, not treatment results.
| Provider & billing terms | Lower listed rate | Higher listed rate | Pharmacy | Reviews & price check | Actions |
|---|---|---|---|---|---|
| WellMedrBest Value Rate Semaglutide $49/mo or tirzepatide $89/mo with 12-month prepayment; $99/$129 month to month. | Lower listed rate$49/mo | Higher listed rate$99 – $129/mo | Pharmacy503A | 4.6/5 1,963 reviews 30 August 2026 | Go WellMedrRead full review |
| SkinnyRx | Lower listed rate$129/mo | Higher listed rate$129/mo | Pharmacy503A partner | 4.4/5 5,335 reviews Check current price | Go SkinnyRxRead full review |
Provider links may earn a commission. Rate sorting compares the displayed numbers, not equivalent treatment plans or total commitments. How we check price terms →
What to know before choosing
The FDA declared the semaglutide shortage resolved in February 2025 and the tirzepatide shortage resolved in May 2025. Those rulings ended the blanket shortage exemption that had allowed 503A and 503B compounding pharmacies to produce copies of Wegovy, Ozempic, Zepbound, and Mounjaro at scale. On April 30, 2026, the FDA proposed removing both active ingredients from the 503B bulks list, a rule that, if finalised, would restrict compounding to 503A pharmacies under the personalisation exception only. This guide explains what each ruling means, what is still legal, and what your options are.
The FDA's shortage-era compounding exemptions for semaglutide and tirzepatide have been winding down since late 2024. The tirzepatide shortage was officially closed in October 2024; the semaglutide shortage was declared resolved in February 2025, and the compounding transition periods ended in April and May 2025. Compounding under the personalisation exception remains legal — but it requires a prescriber to document a specific clinical justification, and not all providers are doing this correctly.
Patients who were previously on compounded GLP-1s and are now being told they need to switch to brand-name Wegovy or Zepbound face a significant cost increase. Brand-name injectables list at $1,300–$1,700/month without insurance. The providers on this list are those that have publicly confirmed they are still dispensing compounded GLP-1s under the personalisation exception as of our most recent review date, with a named pharmacy partner and documented clinical justification workflow.
This list is updated as the regulatory situation evolves. Availability can change quickly — always confirm directly with the provider before starting a programme.
Methodology
This page summarises publicly available FDA regulatory documents, Federal Register notices, and official press releases. We do not interpret legal advice; consult a licensed pharmacist or attorney for specific compliance questions.
Compounded GLP-1 Availability: The Current Regulatory Status
The FDA's removal of semaglutide and tirzepatide from the drug shortage list has created significant confusion about whether compounded GLP-1 medications are still legal. The answer is nuanced — and depends on which pathway the pharmacy is using.
Current Regulatory Status
As of mid-2025, the FDA has removed both semaglutide and tirzepatide from the drug shortage list. This closes the 503A commercial compounding pathway for most telehealth providers. 503B outsourcing facilities have a separate pathway under section 503B of the FD&C Act that does not depend on the shortage list — they can continue to produce compounded versions for office use and distribution to healthcare providers under certain conditions.
The practical result: 503A-based compounded GLP-1 programs are on uncertain legal footing and may face enforcement action. 503B-based programs have a clearer regulatory pathway but are more expensive to operate, which is reflected in pricing.
What This Means for Patients Currently on Compounded GLP-1
If you are currently on a compounded GLP-1 program, the most important question is: what is your clinic's plan if their pharmacy loses the ability to compound? Serious clinics have a transition plan — either to brand-name Wegovy/Zepbound (with insurance navigation support) or to a 503B-sourced alternative. Clinics that have not addressed this question with their patients are not operating with appropriate transparency.
For patients who cannot afford brand-name therapy and whose clinic uses a 503A pharmacy, the risk of supply disruption is real. It is worth asking the question now rather than when the supply is cut off.
Alternatives If Compounded GLP-1 Becomes Unavailable
Brand-name Wegovy and Zepbound are available with manufacturer savings programs (Novo Nordisk's WeGoSupport and Eli Lilly's LillyDirect) that can reduce out-of-pocket costs to $0–$25/month for commercially insured patients. For uninsured patients, the list price is $1,300–$1,600/month.
Oral semaglutide (Rybelsus, 7–14 mg) is FDA-approved for type 2 diabetes and is increasingly used off-label for weight management. It is less effective than injectable semaglutide but is available as a pill and may be covered by insurance for diabetic patients.
The compounded GLP-1 market is in regulatory transition. The clinics in our top tier above are transparent about their pharmacy sourcing and have communicated contingency plans to their patients.
What the Studies Actually Show
The providers listed below offer compounded GLP-1s through 503A pharmacies with documented personalisation rationale, or brand-name GLP-1s as an alternative. Clinical evidence for the active ingredients is summarised below.
| Endpoint | Finding |
|---|---|
| Mean weight loss (STEP 1, 68 weeks, 2.4 mg)1 | −14.9% body weight vs −2.4% placebo in adults with overweight/obesity without diabetes |
| Cardiovascular outcomes (SELECT, ~40 months)2 | 20% relative risk reduction in major adverse cardiovascular events (MACE) in adults with established CV disease and overweight/obesity |
| GI side effects (FDA prescribing information)3 | Nausea ≥10%, diarrhea ≥10%, vomiting ≥10%, constipation ≥10%; most cases mild–moderate and dose-dependent |
| Mean weight loss (SURMOUNT-1, 72 weeks, 15 mg)1 | −20.9% body weight vs −3.1% placebo in adults with obesity without diabetes |
| Mean weight loss with T2D (SURMOUNT-2, 72 weeks, 15 mg)2 | −14.7% body weight in adults with type 2 diabetes |
Frequently Asked Questions
Is compounded semaglutide still legal in 2026?
Yes, with conditions. 503A compounding pharmacies can still compound semaglutide under the personalisation exception, meaning a clinician must document a clinical justification such as a custom dose, a B12 or L-carnitine addition, or a documented intolerance to an inactive ingredient in the commercial product. Bulk compounding without a patient-specific justification is no longer permitted under the shortage exemption. See the FDA shortage resolution notice for the full regulatory background.
What is the April 2026 FDA proposed rule?
On April 30, 2026, the FDA published a proposed rule to remove semaglutide and tirzepatide from the 503B outsourcing facility bulks list. If finalised, 503B facilities, which can compound without a patient-specific prescription and ship in bulk, would no longer be able to produce these drugs. 503A pharmacies filling individual prescriptions with a documented personalisation rationale would still be permitted. The public comment period closes June 29, 2026.
What is the difference between 503A and 503B compounding?
503A pharmacies compound medications for individual patients based on a valid prescription. They are regulated primarily by state boards of pharmacy. 503B outsourcing facilities can produce larger batches without patient-specific prescriptions and are subject to FDA oversight under CGMP standards. The proposed April 2026 rule targets 503B facilities specifically.
Which telehealth providers still offer compounded GLP-1s?
Several telehealth platforms continue to offer compounded semaglutide and tirzepatide through 503A pharmacies under the personalisation exception, including Henry Meds, bmiMD, Eden, MadeMed, and SkinnyRx. Always verify the pharmacy's current licensure and ask your provider about the specific personalisation justification used.
Should I switch to brand-name Wegovy or Zepbound?
If your insurance covers brand-name GLP-1s or you qualify for a manufacturer savings programme, brand-name Wegovy or Zepbound may be a reliable and cost-competitive alternative. Providers such as SkinnyRx, Found Health, FeelGood, and Sesame Care can prescribe brand-name options through telehealth.
- STEP 1 — NEJM 2021 · Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med 2021;384:989–1002.
- SELECT — NEJM 2023 · Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med 2023;389:2221–2232.
- SURMOUNT-1 — NEJM 2022 · Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med 2022;387:205–216.
- SURMOUNT-2 — Lancet 2023 · Garvey WT, Frias JP, Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet 2023;402(10402):613–626.
- SURMOUNT-OSA — NEJM 2024 · Malhotra A, Grunstein RR, Fietze I, et al. Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity. N Engl J Med 2024;391:1193–1205.
- SURPASS — program summary · Frias JP, Davies MJ, Rosenstock J, et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2). N Engl J Med 2021;385:503–515.
RxNotebook is an editorial publication, not a medical practice. We are not affiliated with the cited studies; source material does not endorse the providers shown. This is general information, not medical advice.